Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2018-2028

Global Anti-Obesity Drugs Market Forecast 2018-2028

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

PUBLISHED: 20 November 2018
PAGES: 250
PRODUCT CODE: PHA0343
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0343 Categories: , Tags: , , ,

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Anti-obesity Drugs Market forecast from 2018-2028

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• SNDRIs
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
• Innovator
• Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
• Prescription Drugs
• OTC

• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
• Saxenda
• Contrave/Mysimba
• Belviq
• Qysmia
• Xenical
• Alli

Global Anti-Obesity Drugs Market Forecast 2018-2028

• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
• US
• Japan
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
• RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• Eisai/Arena
• GlaxoSmithKline (GSK)
• Novo Nordisk
• Orexigen/Takeda
• Roche
• Teva
• Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Anti-obesity Drugs Market Analysis : Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028

    Download sample pages

    Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ